November 3, 2021
August 19, 2021
September 2, 2021
September 14, 2021
April 7, 2022
Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization Virtual Event Questions and Answers Friends of Cancer Research (Friends) continues to be committed to improving clinical trial design and drug development to support patients. In September 2021, Friends hosted an event called Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation that highlighted ongoing…
Learn MoreEric Hua | April 5, 2022
On March 29th, Friends of Cancer Research (Friends) convened a virtual meeting to discuss the use of multi-cancer early detection (MCED) screening tests, a promising technology that may support earlier detection of cancers. Dr. Ellen Sigal, Friends’ chair and founder, opened the meeting by highlighting the potential for MCED screening tests to shift the trajectory…
Learn MoreMax Chan | March 3, 2022
On Tuesday, February 22, 2022, Friends of Cancer Research (Friends) hosted a live virtual event that brought together leading voices from various health sectors to discuss key considerations for developing diagnostics tests for rare populations of patients, including those with rare diseases and rare biomarkers. The meeting covered topics surrounding the findings from a recent…
Learn MoreMax Chan | November 15, 2021
On Wednesday, November 10th, Friends of Cancer Research hosted the second day of its 2021 Annual Meeting as a virtual event focused on improving patient outcomes through dose optimization. The first panel discussed the recent white paper on dose optimization and the second panel was a conversation between regulators at the FDA Oncology Center of…
Learn MoreEric Hua | November 15, 2021
On November 9th, Friends of Cancer Research (Friends) held the first of two virtual sessions for their 2021 Annual Meeting, celebrating Friends’ 25th anniversary. The focus of Day 1 was the use of circulating tumor DNA (ctDNA) as an early endpoint. The session opened with a few words of welcome from Friends President and CEO,…
Learn MoreNovember 3, 2021
Each year, the Friends of Cancer Research (Friends) Annual Meeting addresses critical issues in oncology drug development and features experts proposing unique approaches to overcoming current challenges. On Day 2 of the Friends Annual Meeting 2021, panelists will focus on the pressing need for improved dose-finding studies in oncology drug development and discuss proposals to…
Learn MoreBrittany Avin McKelvey | November 3, 2021
The Friends of Cancer Research (Friends) Annual Meeting provides a venue for multiple stakeholders to discuss pressing issues in oncology drug development, providing potential opportunities to overcome challenges and spur future collaborative work. The session on Day 1 of the Friends Annual Meeting 2021 will focus on building a roadmap for the use of changes…
Learn MoreMax Chan | September 29, 2021
On Monday, September 20th, 2021, Friends of Cancer Research (Friends) hosted a virtual event that brought together industry experts, the U.S. FDA, and patient advocates to discuss improving the Breakthrough Therapy designation (BTD) program. The panelists outlined opportunities to enhance the existing expedited drug development programs, including specific recommendations for the BTD, as outlined in…
Learn MoreGrace Collins and Eric Hua | September 14, 2021
This is the second of two blog posts highlighting Friends’ upcoming September 20th event discussing the Breakthrough Therapy designation (BTD). This post will focus on the key challenges between the FDA and drug sponsors that we have identified in our work. Read the first here. The regulatory review process for drugs is a resource intensive…
Learn MoreMax Chan | September 2, 2021
This is the first of two blog posts highlighting Friends’ upcoming September 20th event discussing the Breakthrough Therapy designation (BTD). In this post, we will summarize the recent history of this innovative drug approval pathway and also address potential areas of improvement. BTD is a process that expedites the development and review of drugs intended…
Learn More